>Single Humanized Immune-Checkpoint Mice
- B-hCD274(PD-L1) mice
- PD-L1 is highly expressed in a variety of solid tumors. PD1 and PD-L1 interactions reduce T cell activation and promote tumor immune escape.
- B-hSIRPA mice
- SIRPα binds to its ligand CD47 through the variable IgV-like domains. CD47 is also widely expressed in multiple tissue cells. CD47+ cells activate SIRPα on macrophage surface to prevent its phagocytosis. Previous studies reveal that the diversity of SIRPα is the key to human hematopoietic stem cell suppression, especially tumor suppression. The interruption of SIRPα -CD47 interaction substantially inhibits a variety of tumors. SIRPα/CD47 antibodies are considered as the next star target for tumor immunosuppression following PD-1/PD-L1 antibodies.
- B-hTIGIT mice
- TIGIT is highly expressed in cancer tissues and competitively binds to TIGIT receptors with DNAM-1 proteins on the surface of NK cells to reduce the NK cell killing efficiency of cancer cells.
- B-hHAVCR2 (TIM3) mice
- TIM3 maturation and cell surface expression is facilitated by forming a heterodimeric interaction with CD66a. Co-blockade of CD66a and TIM3 enhanced anti-tumor immune responses, and eliminated tumors in mouse colorectal cancer models.